Medicare has unveiled prices for the first 10 drugs selected for its negotiation program, resulting in discounts of as much as 79% off of list prices. Taxpayers will save an estimated $6 billion, the White House said in its announcement of the new prices. However, these savings will not be immediate, as the new pricing will take effect on January 1, 2026, for those with Medicare Part D prescription drug coverage.
The 10 selected drugs, which include widely used products in therapeutic areas such as diabetes and autoimmune disorders, represent the initial wave of many drugs expected to come under the Medicare negotiating table in years to come. While patient advocacy groups have welcomed the negotiations for the financial relief they bring to Medicare beneficiaries, industry groups and drugmakers have criticized the federal law that initiated the process. The Medicare drug price negotiation is a crucial provision of the Inflation Reduction Act (IRA), signed nearly two years ago by President Biden.
The announcement of the negotiated prices arrives just before the anniversary of President Biden’s signing of the IRA. AARP Executive Vice President Nancy LeaMond has commended the initiative for its potential to bring financial relief to millions of older Americans.
In terms of specific financial impacts, Johnson & Johnson’s immunology drug Stelara saw $9,141 knocked off its list price. Negotiated price cuts ranged from 38% to 79%, with Merck’s diabetes drug Januvia seeing the greatest percent change. According to the Centers for Medicare & Medicaid Services (CMS), if these negotiated prices had been in effect in 2023, they would have saved Medicare an estimated $6 billion off list prices. David Risinger, an analyst at Leerink Partners, noted that savings off net prices equate to about a 22% price reduction in aggregate, which is “not as bad as anticipated earlier this year.”
Jeff Jonas, portfolio manager at Gabelli Funds, highlighted that most of the first 10 drugs are older products near patent expiration, hinting that the greater impact lies ahead as more drugs get selected for negotiation. The program will expand yearly, selecting up to 15 Medicare Part D drugs for negotiation in 2025 and including both Parts B and D drugs in subsequent years.
Looking forward, the industry continues its pushback against these negotiation terms. Despite lawsuits challenging the IRA’s drug price provision as unconstitutional, the pharmaceutical industry remains steadfast in its position against what it considers to be price controls.
Future negotiations are expected to bring more significant impacts, particularly to drugs facing fewer rebates. Analysts like Risinger express concerns about the long-term implications on innovation, especially for oral small molecule drugs that can be selected for negotiation earlier than biologics. The coming rounds of negotiations, encompassing Medicare Part B drugs, could bring steeper price reductions.
Given that further rounds will involve more widely used and innovative medications, stakeholders across the healthcare and pharmaceutical sectors will be closely watching how these negotiations evolve and what impact they will have on drug pricing and pharmaceutical innovation.
For more details, please read the full article.